Pregled bibliografske jedinice broj: 64987
Pretreatment of human peripheral blood lymphocytes with interleukin-2 or dexamethasone does not alter their response to Met-enkephalin in a NK-cytotoxic assay
Pretreatment of human peripheral blood lymphocytes with interleukin-2 or dexamethasone does not alter their response to Met-enkephalin in a NK-cytotoxic assay // Immunopharmacology and immunotoxicology, 18 (1996), 1; 37-58 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 64987 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Pretreatment of human peripheral blood lymphocytes
with interleukin-2 or dexamethasone does not alter
their response to Met-enkephalin in a NK-cytotoxic
assay
Autori
Martin-Kleiner, Irena ; Gabrilovac, Jelka
Izvornik
Immunopharmacology and immunotoxicology (0892-3973) 18
(1996), 1;
37-58
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
NK-cytotoxic assay ; Met-enkephalin ; human peripheral blood lymphocytes ; interelukin-2 ; dexamethasone
Sažetak
The effect of Met-Enkephalin (MENK ; 10(-12) - 10(-8) M) on NK-activity of peripheral blood lymphocytes (PBL) after in vitro treatment (18 h, 37 degrees C) was examined in 30 young, healthy male donors. In the group as a whole (n = 30), no significant effect of MENK was detected. At the individual level, 18 of 30 donors (60%) responded to MENK either by mild enhancement (up to 8%, 8 responders), or by mild attenuation (up to 12%, 10 responders) of the basal NK-activity. The effect of MENK was donor-related regarding the dose- response, E/T ratio, and direction of MENK action. The influence of pretreatment of PBL (1 h) with either graded doses of interleukin-2 (IL-2 ; 3, 25, 50 U/ml) or dexamethasone (Dex ; 2.5 x 10(-9), 2.5 x 10(-8), 2.5 x 10(-7) M), on the effect of MENK was also tested. The idea was that pretreatment of PBL would result in predictable, and/or stronger response to MENK. In the group as a whole again no significant effect of MENK was detected on the NK- activity of PBL prestimulated by IL-2 (n = 16), or inhibited by Dex (n = 12). Further, pretreatment of PBL with IL-2/Dex did not significantly alter the intensity of modulation by MENK, which was generally mild. The data obtained have shown that pretreatment of PBL with IL-2 or Dex, regardless of their concentrations, did not significantly alter the frequency of responders to MENK being 50%, 62.5% and 64.3% with 3, 25 or 50 U/ml IL-2, respectively, and 50% with all concentration of Dex used, as compared to that observed with resting PBL (60%). However, at the individual level physiological concentrations of MENK (10(-12) - 10(-9) M) induced enhancement or/and attenuation of the NK-activity pretreated with IL- 2/Dex, respectively. The effect of MENK at the individual level was donor-related regarding the dose-response, E/T ratio, and direction of MENK action. Thus, pretreatment of PBL with graded concentrations of IL- 2/Dex did not alter the effect of MENK on NK- activity, regarding the frequency and intensity, as well as the direction of modulation: it remained bidirectional, of low intensity, and independent of the grade of PBL preactivation/inhibition, therefore unpredictable.
Izvorni jezik
Engleski
Znanstvena područja
Biologija
Citiraj ovu publikaciju:
Časopis indeksira:
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE
Uključenost u ostale bibliografske baze podataka::
- Chemical Abstracts
- Excerpta Medica
- Index Medicus
- PubMed